Skip to main content
. Author manuscript; available in PMC: 2018 Jul 6.
Published in final edited form as: Nat Rev Urol. 2011 Oct 4;8(11):597–607. doi: 10.1038/nrurol.2011.143

Fig 2. PrlR-signaling in prostate epithelium and current drug development strategies.

Fig 2

The Stat5a/b pathway (see Box 2 for explanations) appears to be the major, if not the only, signaling pathway triggered by the PrlR in mouse and human prostate epithelial cells. Physical interactions between Stat5 and AR have been documented, providing a mechanistic basis for crosstalk between these two pathways resulting in reciprocal synergistic effects. Various levels of inhibition of this signaling cascade are in development (represented in yellow), which involve targeting of PrlR activation (competitive PrlR antagonist), Jak2 activity/stability (Jak2 inhibitors), and Stat5 DNA binding/expression (Stat5 inhibitors).